Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical firm dedicated to drug discovery and development. The company is advancing a pipeline of proprietary drug candidates that harness immune modulation to address significant unmet medical needs, spanning immuno-oncology, organ protection, and regenerative medicine. Its principal product candidates include Traumakine, an intravenous interferon beta-1a therapy, which targets acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant procedures, and ischemia-reperfusion injury.